ENERGY-IMPACT-PARTNERS
16.3.2021 15:17:07 CET | Business Wire | Press release
The Berlin-based Greentech start-up Zolar receives a new investment and adds 10 million euro to the ongoing Series B funding round, raising the total investment of this series to 35 million euro. The new investment is lead by Energy Impact Partners, the biggest investor in the energy sector with offices in the USA and Europe headed by its managing partner Matthias Dill. Existing investors continue to support Zolar in the Series B. With the additional resources, the start-up sets the course for the expansion as a next generation green energy company, focusing on sustainable energy production and integral use of solar energy in private households. Zolar as a consumer brand, is placing customers at the center of energy production, and is driven by its mission of climate protection as a top business priority.
Energy provider of the future– The Next Generation Green Energy Company
The start-up defines five quality criteria, which represent the next generation of energy companies: decentralized renewable energy systems, green and affordable energy, customer centricity, significant reduction in customers’ carbon footprint, with an ultimate goal of carbon neutrality, as well as electrification and smart energy management. By installing a solar system on their own roof, customers are enabled to secure and allocate the main energy requirements of the household. Essential to this is the combination of electric mobility and solar energy, as well as the usage of self-generated power stored in residential batteries. The need for green and sustainably produced energy is also evident, due to rapidly increasing demands from customers. Zolar responds to this trend and offers homeowners an alternative to traditional energy companies, who continue to rely on fossil fuels.
“We find ourselves at the dawn of the solar age” explains Alex Melzer, CEO and co-founder of Zolar. “The solar sector proved to be very stable during the Covid-19 pandemic. In the past year, we have been able to grow our revenue significantly, and in 2021, we are targeting to triple installations across Germany. With the fresh 10 million, we are taking the company to the next level and The investment of Energy Impact Partners shows that investors recognise the relevance of regenerative energy. In doing so, they support us to grow quicker, accelerate revenue growth while at the same time having a positive impact on climate protection. Because ultimately what drives us all, is a livable future for all humans”, continued Melzer.
Private households become energy suppliers
In order for every household to become its own energy supplier, Zolar relies on technological platform solutions across the whole value chain. With full service digital concept, beginning with the Zolar Online Configurator, from a holistic customer journey to roof installation via the partner platform Zolar Project Center. The company intends to establish itself as a leading customer brand in the energy sector and is planning an expansion of the core business. In keeping with the requirement of an electrified household, the product portfolio will facilitate an integration of energy production, power storage and mobility.
“Zolar is one of the fastest growing energy start-ups in Germany”, added Matthias Dill, Managing Partner of Energy Impact Partners. “At Energy Impact Partners we closely monitor the transformation of the energy sector and with this investment we intend to provide ongoing support for Zolar’s goal – to become the energy provider of the future. The combination of technological state-of-the-art platforms, customer success and climate protection is a clear formula for success for us” continued Dill.
About Zolar
The Greentech start-up Zolar offers fixed-priced photovoltaic systems, which home owners can plan, compare and commission online, according to their needs. With the help of the in-house developed Zolar Online Configurator, homeowners have the possibility to adjust the components of their PV system according to their wishes, and along with this, receive an individual consultation from solar experts. Zolar’s wide network of local partner businesses carries out the installation on-site. The Berlin start-up employs around 150 employees across Germany and pursues the vision, to install solar panelling on every roof in the world, granting private households greater independence from energy supply systems. The gearing of energy production, energy storage and mobility enables the customer to design an electrified and smart household. As a next green energy company, Zolar empowers its customers to become energy suppliers within its own four walls, to neutralize their carbon footprint and to make an impact towards climate protection.
More information at: http://www.zolar.de
About Energy Impact Partners
Energy Impact Partners (EIP) is a global investment platform leading the transition to a sustainable energy future. EIP brings together entrepreneurs and the world's most forward-looking energy and industrial companies to advance innovation. With over $1.5 billion in assets under management, EIP invests globally across venture, growth, credit and infrastructure – and has a team of more than 45 professionals based in its offices in New York, San Francisco, Palm Beach, London, and Cologne.
For more information on EIP, please visit: www.energyimpactpartners.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210316005732/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom